Polyrizon Ltd. signed its first U.S. Clinical Trial Agreement with a Texas-based site for the NASARIX™ Allergy Blocker multi-center study, advancing toward first-in-human clinical trials.
Key takeaways
Signed first Clinical Trial Agreement (CTA) with U.S. clinical research site in Texas specializing in allergy studies.
Site will be first participating center in multi-center study evaluating safety, tolerability, and efficacy of NASARIX™ (PL-14) in seasonal allergic rhinitis patients.
Study titled 'Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray'.
Additional clinical sites expected in coming months; trial per GCP standards.
NASARIX™ is non-pharmacological intranasal hydrogel barrier against allergens.